JP2022532706A5 - - Google Patents

Info

Publication number
JP2022532706A5
JP2022532706A5 JP2021566558A JP2021566558A JP2022532706A5 JP 2022532706 A5 JP2022532706 A5 JP 2022532706A5 JP 2021566558 A JP2021566558 A JP 2021566558A JP 2021566558 A JP2021566558 A JP 2021566558A JP 2022532706 A5 JP2022532706 A5 JP 2022532706A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566558A
Other languages
English (en)
Japanese (ja)
Other versions
JP7574223B2 (ja
JP2022532706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031904 external-priority patent/WO2020227549A1/en
Publication of JP2022532706A publication Critical patent/JP2022532706A/ja
Publication of JP2022532706A5 publication Critical patent/JP2022532706A5/ja
Priority to JP2024180616A priority Critical patent/JP7844578B2/ja
Application granted granted Critical
Publication of JP7574223B2 publication Critical patent/JP7574223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566558A 2019-05-08 2020-05-07 THR-βの調節物質およびその使用方法 Active JP7574223B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180616A JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US62/845,252 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US62/944,052 2019-12-05
US202063005661P 2020-04-06 2020-04-06
US63/005,661 2020-04-06
PCT/US2020/031904 WO2020227549A1 (en) 2019-05-08 2020-05-07 MODULATORS OF THR-β AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180616A Division JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022532706A JP2022532706A (ja) 2022-07-19
JP2022532706A5 true JP2022532706A5 (cg-RX-API-DMAC10.html) 2023-05-12
JP7574223B2 JP7574223B2 (ja) 2024-10-28

Family

ID=70919081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566558A Active JP7574223B2 (ja) 2019-05-08 2020-05-07 THR-βの調節物質およびその使用方法
JP2024180616A Active JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180616A Active JP7844578B2 (ja) 2019-05-08 2024-10-16 THR-βの調節物質およびその使用方法

Country Status (32)

Country Link
US (3) US11091467B2 (cg-RX-API-DMAC10.html)
EP (2) EP4523692A3 (cg-RX-API-DMAC10.html)
JP (2) JP7574223B2 (cg-RX-API-DMAC10.html)
KR (1) KR102968107B1 (cg-RX-API-DMAC10.html)
CN (2) CN122036699A (cg-RX-API-DMAC10.html)
AU (1) AU2020267576B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021021718A2 (cg-RX-API-DMAC10.html)
CA (1) CA3139101A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002883A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021015698A2 (cg-RX-API-DMAC10.html)
DK (1) DK3965884T3 (cg-RX-API-DMAC10.html)
ES (1) ES3020290T3 (cg-RX-API-DMAC10.html)
FI (1) FI3965884T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20247637B (cg-RX-API-DMAC10.html)
HR (1) HRP20250384T1 (cg-RX-API-DMAC10.html)
HU (1) HUE070650T2 (cg-RX-API-DMAC10.html)
IL (1) IL287720A (cg-RX-API-DMAC10.html)
LT (1) LT3965884T (cg-RX-API-DMAC10.html)
MA (1) MA55890B1 (cg-RX-API-DMAC10.html)
MD (1) MD3965884T2 (cg-RX-API-DMAC10.html)
MX (1) MX2021013472A (cg-RX-API-DMAC10.html)
MY (1) MY210357A (cg-RX-API-DMAC10.html)
PE (1) PE20220255A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552782A1 (cg-RX-API-DMAC10.html)
PL (1) PL3965884T3 (cg-RX-API-DMAC10.html)
PT (1) PT3965884T (cg-RX-API-DMAC10.html)
RS (1) RS66686B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202111552YA (cg-RX-API-DMAC10.html)
SI (1) SI3965884T1 (cg-RX-API-DMAC10.html)
TW (1) TWI855068B (cg-RX-API-DMAC10.html)
WO (1) WO2020227549A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202409114B (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) * 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2021244582A1 (zh) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 新型甲状腺激素β受体激动剂
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
EP4215524A4 (en) * 2020-09-17 2024-10-02 Sunshine Lake Pharma Co., Ltd. COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF THE COMPOUND
US11793815B2 (en) 2020-11-06 2023-10-24 Aligos Therapeutics, Inc. Oxindoles and methods of use thereof
AU2021376281A1 (en) 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Pyridazinone derivatives as thyroid receptor agonists and uses thereof
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450B (zh) * 2020-12-30 2026-06-16 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
WO2022184177A1 (zh) * 2021-03-04 2022-09-09 甫康(上海)健康科技有限责任公司 一种芳香化合物、其制备方法及其应用
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1,2,4-三嗪-3,5-二酮类化合物的盐型、晶型及其制备方法
TW202313615A (zh) * 2021-05-21 2023-04-01 大陸商深圳微芯生物科技股份有限公司 一種雜環化合物及其應用
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
US20250243491A1 (en) 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
CA3230382A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
TWI910297B (zh) * 2021-12-24 2026-01-01 大陸商廣東東陽光藥業股份有限公司 一種作為甲狀腺激素β受體激動劑的化合物及其用途
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN119137113A (zh) * 2022-02-10 2024-12-13 马德里加尔制药公司 THRβ类似物及其用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024182446A2 (en) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN121358734A (zh) * 2023-06-19 2026-01-16 西威埃医药技术(上海)有限公司 THR-β受体激动剂、其制备方法和其使用方法
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN117327057B (zh) * 2023-08-30 2026-03-03 南京雷正医药科技有限公司 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途
WO2025137568A1 (en) * 2023-12-21 2025-06-26 Aligos Therapeutics, Inc. Modulators of thr-beta and methods of use thereof
TW202604525A (zh) 2024-05-03 2026-02-01 美商艾利格斯醫療公司 製備THR-β調節劑之方法
WO2025252147A1 (zh) * 2024-06-07 2025-12-11 珠海联邦制药股份有限公司 一种甲状腺激素β受体激动剂的化合物及其应用
WO2026050911A1 (zh) * 2024-09-04 2026-03-12 西威埃医药技术(上海)有限公司 一种TR-β选择性激动剂的晶型、制备方法和应用
WO2026067791A1 (en) 2024-09-30 2026-04-02 Ascletis Pharma (China) Co., Limited 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity
US20260102403A1 (en) 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
CA2473162A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
WO2004047827A1 (en) 2002-11-25 2004-06-10 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
JP2009521448A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
CN101506158A (zh) * 2006-06-28 2009-08-12 株式会社三和化学研究所 新6-5系二环式杂环衍生物及其医药用途
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
EP3019196B1 (en) 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
MX2017008844A (es) 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
KR102444366B1 (ko) 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US11808772B2 (en) 2017-07-19 2023-11-07 Bio-Rad Europe Gmbh Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
WO2019099457A1 (en) 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
EP3765059A4 (en) 2018-03-12 2022-01-12 Yale University METHODS OF TREATMENT OR PREVENTION OF ACUTE RESPIRATORY SYNDROME
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
EP3806832A1 (en) 2018-06-14 2021-04-21 Alma Mater Studiorum - Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
US20210292304A1 (en) 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202615431A (zh) 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN112300133B (zh) 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP4019524A4 (en) 2019-08-19 2024-01-03 Hepagene Therapeutics (HK) Limited HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021057791A1 (zh) 2019-09-24 2021-04-01 广东东阳光药业有限公司 一种作为甲状腺激素Beta受体激动剂的化合物及其用途
CN112707892A (zh) 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CA3158379A1 (en) 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
MX2022012469A (es) 2020-04-06 2022-10-27 Basf Se Compuestos de imidazo-pirimidona como plaguicidas.

Similar Documents

Publication Publication Date Title
CN113507931B (zh) 调节短链脱氢酶活性的组合物和方法
JP7835895B2 (ja) Parp1を選択的に阻害するフルオロキノキサリノン誘導体
WO2020094104A1 (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
JP2021531256A (ja) NaV1.8を阻害するピリダジン化合物
JP2021527638A (ja) B型肝炎カプシドアセンブリモジュレーター
AU2019233207B2 (en) Heteroaryl compounds as kinase inhibitor
ES3062921T3 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
BRPI0710231A2 (pt) composto, composição farmacêutica, e, intermediário para a preparação de um composto
EA020138B1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
FR2943669A1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
CN104011019B (zh) 吡咯衍生物
JP2005119987A (ja) アシルスルホンアミド誘導体
TW202214626A (zh) 雌激素受體調節劑化合物及其用途
JP2018510131A (ja) Rorc2のスルホンアミド置換インドールモジュレーターおよびその使用方法
TW202415647A (zh) 抑制Bcl-2或Bcl-xL的化合物及其在醫藥上的應用
IL293497A (en) Compounds for the activity module of fxr and its uses
JP2020519697A (ja) インドリジン誘導体及びその医学的応用
JP2014525418A (ja) タンパク質キナーゼ阻害活性を有する4−置換−(3−置換−1h−ピラゾール−5−アミノ)−ピリミジン誘導体及びその使用
CA2901766A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors
MX2007015705A (es) Derivados biciclicos como inhibidores de la cinasa p38.
JP2020520388A (ja) Ldha活性阻害剤
CN119110795A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
JP2021519825A (ja) 輸送体の調節薬としての二環式エノンカルボキシラートとその使用
WO2025098417A1 (zh) 磺酰胺类化合物及其应用
WO2025162280A1 (zh) 吡唑羧酸衍生物及其在医药上的应用